VIDEO: Qlosi for presbyopia demonstrates near vision improvement, pupil size reduction
Click Here to Manage Email Alerts
CHICAGO — In this Healio Video Perspective from the AAO meeting, Jennifer M. Loh, MD, shares results from the NEAR phase 3 clinical trials, which investigated Qlosi, a low-dose pilocarpine eye drop for the treatment of presbyopia.
The study investigated Qlosi’s (pilocarpine hydrochloride ophthalmic solution 0.4%, Orasis Pharmaceuticals) effect on pupil size reduction and changes in best corrected near visual acuity over the course of the 15-day study period, with a linear improvement throughout the study, especially between day 1 and day 8, according to Loh.
“We thought that this could be due to neuroadaptation with the product,” she said. “We believe it could be important to use the product consistently for our patients so they can start to experience that improvement in the near vision.”
Collapse
Loh JM, et al. Optimal pupil size reduction percentage for near vision improvement in presbyopia: NEAR phase 3 clinical trials. Presented at: American Academy of Ophthalmology meeting; Oct. 18-21, 2024; Chicago.
Read more about
Click Here to Manage Email Alerts